The Advanced Practice Provider Perspective: Treating Patients With Immuno-Oncology Combination Therapy Across Tumor Types

BRIANNA HOFFNER,1 MSN, ANP-BC, AOCNP®, RENAE VAUGHN,2 MSN, ANP-C, AOCNP®, MAUREEN REED,3 MSN, ANP-C, AOCNP®, and MELINDA S. WEBER,4 DNP, RN, APN, AOCN®

From 1University of Colorado Cancer Center, Denver, Colorado; 2Munson Medical Center, Traverse City, Michigan; 3Tennessee Oncology/Sarah Cannon Research Institute, Nashville, Tennessee; and 4John Theurer Cancer Center, Hackensack, New Jersey

Authors’ disclosures of conflicts of interest are found at the end of this article.

Correspondence to: Brianna Hoffner, MSN, ANP-BC, AOCNP®, 1201 Larimer Street, Denver, CO 80204. E-mail: brianna.hoffner@ucdenver.edu

https://doi.org/10.6004/jadpro.2019.10.4.5

© 2019 Harborside™

Abstract

A number of immune checkpoint inhibitors (ICIs) have been approved by the U.S. Food and Drug Administration (FDA) as immuno-oncology (IO) monotherapy for multiple solid and hematologic tumor types across various lines of therapy. Furthermore, evidence shows some patients may derive additional benefit from IO combination therapy. Three IO combination regimens, nivolumab plus ipilimumab, and pembrolizumab or atezolizumab plus chemotherapy, are approved by the FDA as of April 2019. Because peripheral immune surveillance via T-cell activity is increased to attack malignant cells, the antitumor effects of ICIs may be accompanied by immune-mediated adverse reactions (IMARs). Although potentially more efficacious than monotherapy, IO combination therapies are associated with increased incidences of IMARs vs. IO monotherapy. Advanced practice providers (APPs) are uniquely placed within the multidisciplinary team to counsel patients with cancer on their IO treatment and educate them about identifying manifestations of IMARs. Advanced practice providers should be aware of the presentation and time to onset of IMARs, appropriate management to reduce risk of organ dysfunction, and guidelines for treating these patients. This article reviews IO/IO and IO/chemotherapy combination regimens with respect to clinical efficacy and safety, and discusses the role of the APP in managing IMARs associated with IO combination therapy.

Immuno-oncology (IO) is an evolving treatment modality that includes immunotherapies able to directly target and harness the patient’s immune system to kill tumor cells (Antonia, Larkin, & Ascierto, 2014). Several IO agents, many of which

Immuno-oncology (IO) is an evolving treatment modality that includes immunotherapies able to directly target and harness the patient’s immune system to kill tumor cells (Antonia, Larkin, & Ascierto, 2014). Several IO agents, many of which
were approved through accelerated regulatory processes (Table 1; U.S. Department of Health and Human Services; U.S. Food and Drug Administration), are available in the United States (US) for the treatment of various types of solid and hematologic malignancies. These include anti–programmed cell death protein 1 (PD-1) antibodies nivolumab (Opdivo), pembrolizumab (Keytruda), and cemiplimab-rwlc (Libtayo); anti–programmed cell death ligand 1 (PD-L1) antibodies atezolizumab (Tecentriq), durvalumab (Imfinzi), and avelumab (Bavencio); and anti–cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) antibody ipilimumab (Yervoy; AstraZeneca UK Limited, 2018; Bristol-Myers Squibb, 2018, 2019; EMD Serono Inc, 2018; Genentech, 2019; Merck & Co Inc, 2019; Regeneron Pharmaceuticals Inc and sanofi-aventis US LLC, 2019).

Immune checkpoint inhibitors (ICIs), a type of IO therapy, target proteins such as CTLA-4, PD-1, and PD-L1 (Kreamer, 2014; Langer, 2015), among other checkpoints. By targeting these proteins, which regulate T-cell immune function, and blocking the interaction with their ligands, ICIs release pathway-mediated inhibition of the antitumor immune response (Kreamer, 2014; Langer, 2015). The mechanisms of action of CTLA-4, PD-L1, and PD-1 ICIs are shown in Figure 1.

Immuno-oncology monotherapy or in combination with another agent have various indications across advanced or metastatic tumor types, as well as in the adjuvant setting (AstraZeneca UK Limited, 2018; Bristol-Myers Squibb, 2018, 2019; EMD Serono Inc, 2018; Genentech, 2019; Merck & Co Inc, 2019; Regeneron Pharmaceuticals Inc and sanofi-aventis US LLC, 2019). Clinical trial data demonstrated that patients with certain types of cancers, such as melanoma, renal cell carcinoma (RCC), microsatellite instability–high or mismatch repair–deficient (MSI-H/dMMR) colorectal cancer (CRC), non–small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), may derive additional benefit from IO/IO or IO/chemotherapy combination therapy (Antonia et al., 2016; Gandhi et al., 2018; Langer et al., 2016; Larkin et al., 2015; Motzer et al., 2018; Overman et al., 2017, 2018; Postow et al., 2015; Wolchok et al., 2017).

In animal models, combined anti–PD-1- and anti–CTLA-4-mediated inhibition was shown to enhance T-cell function greater than the effects of either antibody alone (Bristol-Myers Squibb, 2019). In vitro and in vivo evidence from humans and murine models suggest that chemotherapy induces PD-L1 expression on tumor cells and causes immunogenic tumor cell death (Aoto et al., 2018; Grabosch et al., 2015; Peng et al., 2015; Zhang et al., 2016). When combined with immunotherapy, chemotherapy may have an additive effect on the
### Table 1. Comparison of FDA Expedited Programs for Serious Conditions

| Program          | Nature of program | Description                                                                 | Features                                                                 | Time for FDA to take action on marketing application | Immuno-oncology examples                                      |
|------------------|-------------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------|-------------------------------------------------------|---------------------------------------------------------------|
| Fast Track       | Designation       | Facilitates the development and expedites the review of drugs to treat serious conditions and fill an unmet medical need | - Increased communication with the FDA<br>- Eligibility for Accelerated Approval and Priority Review, if relevant criteria are met<br>- Rolling Review<sup>a</sup> | Not specified                                            | • Avelumab approved for MCC<br>• Nivolumab approved for NSCLC, RCC, and melanoma<br>• Durvalumab approved for PD-L1+ SCCHN |
| Priority Review  | Designation       | Directs overall attention and resources to evaluating drug applications that, if approved, would mean significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions vs. standard applications | - FDA intends to take action (approve/reject) on an application within 6 months (compared with 10 months under standard review) | 6 months                                                | • Nivolumab approved for melanoma (adjuvant and metastatic), NSCLC, RCC, UC, SCCHN, SCLC, and cHL<br>• Durvalumab approved for NSCLC<br>• Nivolumab plus ipilimumab approved for RCC and CRC |

<sup>a</sup> Rolling Review: a drug company can submit completed sections of its BLA or NDA for review by the FDA, rather than waiting until every section of the NDA is completed before the entire application can be reviewed. BLA or NDA review usually does not begin until the drug company has submitted the entire application to the FDA.

---

**Note.** FDA = U.S. Food and Drug Administration; MCC = Merkel cell carcinoma; NSCLC = non–small cell lung cancer; RCC = renal cell carcinoma; PD-L1 = programmed cell death ligand 1; SCCHN = squamous cell carcinoma of the head and neck; UC = urothelial carcinoma; SCLC = small cell lung cancer; chL = classical Hodgkin lymphoma; CRC = colorectal cancer; NSQ = nonsquamous; PMBCL = primary mediastinal large B-cell lymphoma; MSI-H = microsatellite instability-high; dMMR = mismatch repair deficient; HCC = hepatocellular carcinoma; GC = gastric cancer; G(EJ)C = gastric or gastroesophageal junction adenocarcinoma; BLA = Biologic License Application; NDA = New Drug Application. Information from AstraZeneca UK Limited (2018); Bristol-Myers Squibb (2018, 2019); Chaudhari (2017); EMD Serono Inc (2018); Genentech (2019); Merck & Co Inc (2019); U.S. Department of Health and Human Services (2014); U.S. Food and Drug Administration (2018a, 2018b).

<sup>Table continued on the following page</sup>
### Table 1. Comparison of FDA Expedited Programs for Serious Conditions (cont.)

| Program               | Nature of program | Description                                                                 | Features                                                                                          | Time for FDA to take action on marketing application | Immuno-oncology examples                                                                 |
|-----------------------|-------------------|----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|------------------------------------------------------|------------------------------------------------------------------------------------------|
| Breakthrough Therapy  | Designation       | Expedites development and review of drugs intended to treat a serious condition and have preliminary clinical evidence indicating that they may demonstrate substantial improvement over available therapy on clinically significant endpoints | • All Fast Track designation features  
• Intensive guidance on an efficient drug development program   | Not specified                                                                                      | • Nivolumab approved for SCCHN, chL, melanoma, NSQ NSCLC, RCC, and UC  
• Pembrolizumab approved for MCC, PMBCL, MSI-H/dMMR solid tumors, UC, chL, melanoma, and PD-L1+ NSCLC  
• Nivolumab plus ipilimumab approved for RCC and MSI-H/dMMR CRC  
• Durvalumab approved for UC and NSCLC  
• Avelumab approved for MCC  
• Atezolizumab approved for NSCLC and UC |
| Accelerated Approval  | Approval pathway  | Allows drugs for serious conditions that fill an unmet medical need to be approved based on whether a drug has an effect on a surrogate or intermediate clinical endpoint | • Using a surrogate or intermediate clinical endpoint enables the FDA to approve these drugs faster  
• Additional postmarketing clinical trials may be required to verify and describe the drug’s clinical benefit | Not specified                                                                                      | • Nivolumab approved for melanoma, chL, UC, MSI-H/dMMR CRC, HCC, and SCLC  
• Pembrolizumab approved for melanoma and MSI-H/dMMR CRC  
• Nivolumab plus ipilimumab approved for melanoma and MSI-H/dMMR CRC  
• Pembrolizumab approved for MCC, HCC, PD-L1+ G(EJ)C, MSI-H/dMMR solid tumors, NSQ NSCLC, PD-L1+ NSCLC, melanoma, SCCHN, chL, PMBCL, UC, and cervical cancer  
• Pembrolizumab plus chemotherapy approved for NSQ NSCLC  
• Atezolizumab approved for UC  
• Durvalumab approved for NSCLC and UC  
• Avelumab approved for UC and MCC |

Note. FDA = U.S. Food and Drug Administration; MCC = Merkel cell carcinoma; NSCLC = non–small cell lung cancer; RCC = renal cell carcinoma; PD-L1 = programmed cell death ligand 1; SCCHN = squamous cell carcinoma of the head and neck; UC = urothelial carcinoma; SCLC = small cell lung cancer; chL = classical Hodgkin lymphoma; CRC = colorectal cancer; NSQ = nonsquamous; PMBCL = primary mediastinal large B-cell lymphoma; MSI-H = microsatellite instability-high; dMMR = mismatch repair deficient; HCC = hepatocellular carcinoma; GC = gastric cancer; G(EJ)C = gastric or gastroesophageal junction adenocarcinoma; BLA = Biologic License Application; NDA = New Drug Application. Information from AstraZeneca UK Limited (2018); Bristol-Myers Squibb (2018, 2019); Chaudhari (2017); EMD Serono Inc (2018); Genentech (2019); Merck & Co Inc (2019); U.S. Department of Health and Human Services (2014); U.S. Food and Drug Administration (2018a, 2018b).

*Rolling Review: a drug company can submit completed sections of its BLA or NDA for review by the FDA, rather than waiting until every section of the NDA is completed before the entire application can be reviewed. BLA or NDA review usually does not begin until the drug company has submitted the entire application to the FDA.*
antitumor activity of anti–PD-1 and anti–PD-L1 monotherapy (Apetoh, Ladoire, Coukos, & Ghiringhelli, 2015). In clinical trials, the combination of nivolumab plus ipilimumab resulted in improved antitumor responses in metastatic melanoma, advanced RCC, and MSI-H/dMMR metastatic CRC (Bristol-Myers Squibb, 2019; Larkin et al., 2015; Motzer et al., 2018; Overman et al., 2017, 2018; Wolchok et al., 2017); improved antitumor responses also were seen in squamous and nonsquamous NSCLC with pembrolizumab plus chemotherapy (Gandhi et al., 2018; Langer et al., 2016; Paz-Ares et al., 2018). As a result of these studies, the U.S. Food and Drug Administration (FDA) approved nivolumab in combination with ipilimumab for the treatment of melanoma, RCC, and MSI-H/dMMR CRC; and pembrolizumab in combination with pemetrexed and platinum chemotherapy for nonsquamous NSCLC and in combination with carboplatin and either paclitaxel or nanoparticle albumin-bound paclitaxel (nab-paclitaxel) for squamous NSCLC (Bristol-Myers Squibb, 2018, 2019; Merck & Co Inc, 2019). Notably, dosing schedule and infusion duration with nivolumab in combination with ipilimumab vary by indication, underscoring the importance of consulting updated prescribing information (Bristol-Myers Squibb, 2019).

As depicted in Figure 1, ICIs increase T-cell and other effector cell activity to attack malignant cells (Kreamer, 2014; Langer, 2015). However, healthy, nonmalignant cells may also be subject to attack (Postow, Sidlow, & Hellmann, 2018). Therefore, antitumor effects may be accompanied by immune-mediated adverse reactions (IMARs) that can lead to organ dysfunction or death if left untreated (Gandhi et al., 2018; Postow et al., 2018). IO/IO and IO/chemotherapy combination therapies, in particular, are associated with increased incidences of IMARs compared with IO monotherapy (Gandhi et al., 2018; Larkin et al., 2015). Although a number of resources provide information specifically related to the optimal management of patients receiving IO combination therapy, few focus on the role of advanced practice providers (APPs), including nurse practitioners, physician assistants, and pharmacists (Brahmer et al., 2018; Haanen et al., 2017; Puzanov et al., 2017). Here, we review the clinical efficacy and safety/tolerability of approved IO/IO and IO/chemotherapy combinations and discuss the role of the APP in educating patients about their cancer treatments and managing IMARs associated with IO combination therapy.

CLINICAL EFFICACY OF APPROVED IO COMBINATION THERAPY

In the randomized, double-blind, phase III CheckMate 067 trial of patients with unresectable stage III or IV melanoma, 4-year median progression-free survival (PFS) was significantly longer with both nivolumab at 1 mg/kg plus ipilimumab at 3 mg/kg (37%) and nivolumab at 3 mg/kg monotherapy (31%) compared with ipilimumab at 3 mg/kg alone (9%; Hodi et al., 2018). Nivolumab plus ipilimumab and nivolumab monotherapy also both significantly improved overall survival (OS) compared with ipilimumab alone in patients both with and without BRAF mutations (53%, 46%, and 30%, respectively; Hodi et al., 2018). In addition, a significantly greater proportion of patients who received combination therapy achieved an objective response (58%) compared with ipilimumab monotherapy (19%; Hodi et al., 2018). Furthermore, a significantly greater proportion of patients treated with nivolumab monotherapy achieved an objective response (45%) compared with ipilimumab alone (19%; Hodi et al., 2018). The median duration of response was 50.1 months with nivolumab plus ipilimumab, not reached with nivolumab monotherapy, and 14.4 months in the ipilimumab group (Hodi et al., 2018).

In the randomized, double-blind, phase II CheckMate 069 study, significantly more patients with BRAF wild-type metastatic melanoma who received nivolumab at 1 mg/kg plus ipilimumab at 3 mg/kg every 3 weeks achieved an objective response (61%) compared to ipilimumab at 3 mg/kg every 3 weeks monotherapy (11%; Postow et al., 2015). Complete responses were reported in 22% of the combination group and no patients in the ipilimumab monotherapy group (Postow et al., 2015). Median PFS was also significantly prolonged in the combination group (Postow et al., 2015). Similar results for response rates were observed in 33 patients with BRAF mutation–positive tumors (Postow et al., 2015).
The randomized, open-label, phase III CheckMate 214 trial evaluated patients with International Metastatic RCC Database Consortium (IMDC) intermediate and poor risk who had advanced clear-cell RCC (Motzer et al., 2018). Patients receiving nivolumab at 3 mg/kg plus ipilimumab at 1 mg/kg every 3 weeks had a significantly higher objective response rate (ORR; 42% vs. 27%), higher complete response rate (9% vs. 1%), longer median PFS (11.6 months vs. 8.4 months), and longer median OS (not reached vs. 26.0 months) vs. sunitinib at 50 mg daily (Motzer et al., 2018). The median duration of response was not reached with combination therapy and was 18.2 months with sunitinib (Motzer et al., 2018). In the intention-to-treat (ITT) population, including IMDC favorable-risk patients, nivolumab plus ipilimumab resulted in a higher ORR and longer OS vs. sunitinib, and survival benefits were observed irrespective of PD-L1 expression (Motzer et al., 2018).

In the open-label, multicohort, phase II CheckMate 142 trial, patients with MSI-H/dMMR metastatic CRC who were treated with nivolumab at 3 mg/kg plus ipilimumab at 1 mg/kg every 3 weeks showed numerically higher response rates (55%) compared with a similar population of patients receiving nivolumab at 3 mg/kg every 2 weeks alone (31%; Overman et al., 2017, 2018). However, the two treatment groups were not directly compared to evaluate statistical significance. The median duration of response was not reached in either group (Overman et al., 2017, 2018).

In the randomized, double-blind, phase III KEYNOTE-189 study, patients with metastatic nonsquamous NSCLC received pemetrexed at 500 mg/m² and carboplatin area under the curve (AUC) 5 mg/mL/min or cisplatin at 75 mg/m² with or without pembrolizumab at 200 mg every 3 weeks (Gandhi et al., 2018). At a median follow-up of 10.5 months, median PFS and OS were significantly longer with pembrolizumab combination therapy vs. chemotherapy alone. Survival and PFS benefits were observed with pembrolizumab combination therapy regardless of PD-L1 expression (Gandhi et al., 2018). A significantly higher proportion of patients who received combination therapy achieved an objective response (48%) compared with chemotherapy alone (19%; Gandhi et al., 2018). The median durations of response were 11.2 and 7.8 months, respectively (Gandhi et al., 2018).

In KEYNOTE-021, a randomized, open-label, phase II study of patients with stage IIIB or IV nonsquamous NSCLC, significantly more patients who received pembrolizumab at 200 mg plus carboplatin AUC 5 mg/mL/min and pemetrexed at 500 mg/m² every 3 weeks achieved a greater objective response (55%) compared with chemotherapy alone (29%; Langer et al., 2016). The median duration of response was not reached in either group (Langer et al., 2016). Additionally, PFS was significantly longer in the combination group compared with chemotherapy alone (62% vs. 48%); however, no significant difference in OS was observed between groups (Langer et al., 2016).

In the randomized, double-blind, phase III KEYNOTE-407 study, patients with previously untreated metastatic squamous NSCLC received carboplatin AUC 6 mg/mL/min plus either paclitaxel at 200 mg/m² or nab-paclitaxel at 100 mg/m² with or without pembrolizumab at 200 mg every 3 weeks (Paz-Ares et al., 2018). After a median follow-up of 7.8 months, median PFS (6.4 vs. 4.8 months) and OS (15.9 vs. 11.3 months) were significantly longer with pembrolizumab combination therapy than chemotherapy alone (Paz-Ares et al., 2018). PD-L1 expression had no impact on the survival benefit with combination therapy. Furthermore, a greater proportion of patients who received pembrolizumab plus chemotherapy achieved a greater objective response (58%) compared with chemotherapy alone (38%). The median duration of response was 7.7 months in the pembrolizumab-combination group and 4.8 months in the chemotherapy group (Paz-Ares et al., 2018).

Table 2 summarizes the clinical efficacy of FDA–approved IO combination therapies.

SAFETY PROFILE OF APPROVED IO COMBINATION THERAPY

In CheckMate 067, a similar proportion of patients with melanoma in the nivolumab at 1 mg/kg plus ipilimumab at 3 mg/kg every 3 weeks, nivolumab at 3 mg/kg every 2 weeks, and ipilimumab at 3 mg/kg every 3 weeks groups experienced any-grade IMARs, defined as select adverse events (AEs; i.e., those with a potential immunologic cause; Wol-
### Table 2. Clinical Efficacy of FDA-Approved Immuno-Oncology Combination Therapies

| Study                  | Design                          | Tumor type                                    | Interventions (N)               | Primary endpoints | Key secondary endpoints |
|------------------------|---------------------------------|-----------------------------------------------|---------------------------------|-------------------|-------------------------|
| CheckMate 067          | Randomized, double-blind, phase III study | Previously untreated unresectable stage III or IV melanoma | NIVO 1 mg/kg (N = 314) + IPI 3 mg/kg vs. NIVO 3 mg/kg (N = 316) vs. IPI 3 mg/kg (N = 315) | PFS               | ORR                     |
| (Hodi et al., 2018)    |                                 |                                               | NIVO + IPI                      |                   | NIVO + IPI              |
|                        |                                 |                                               | • Median, 11.5 mo (95% CI = 8.7–19.3) |                   | • OR (95% CI = 52.6–63.8) |
|                        |                                 |                                               | • HR vs. IPI, 0.42 (95% CI = 0.35–0.51; p < .0001) |                   | • OR vs. IPI, 6.35 (95% CI = 4.38–9.22; p < .0001) |
|                        |                                 |                                               | IPI                             |                   |                         |
|                        |                                 |                                               | • Median, 6.9 mo (95% CI = 5.1–10.2) |                   |                         |
|                        |                                 |                                               | • HR vs. IPI, 0.53 (95% CI = 0.44–0.64; p < .0001) |                   |                         |
|                        |                                 |                                               | IPI                             |                   |                         |
|                        |                                 |                                               | • Median, 2.9 mo (95% CI = 2.8–3.2) |                   |                         |
|                        |                                 |                                               | ORR                             |                   |                         |
|                        |                                 |                                               | NIVO + IPI                      |                   |                         |
|                        |                                 |                                               | • Median, NR (95% CI = 38.2–NR) |                   |                         |
|                        |                                 |                                               | • HR vs. IPI, 0.54 (95% CI = 0.44–0.67; p < .0001) |                   |                         |
|                        |                                 |                                               | IPI                             |                   |                         |
|                        |                                 |                                               | • Median, 36.9 mo (95% CI = 28.3–NR) |                   |                         |
|                        |                                 |                                               | • HR vs. IPI, 0.65 (95% CI = 0.53–0.79; p < .0001) |                   |                         |
|                        |                                 |                                               | IPI                             |                   |                         |
|                        |                                 |                                               | • Median, 19.9 mo (95% CI = 16.9–24.6) |                   |                         |
| CheckMate 069          | Randomized, double-blind, phase II study | Previously untreated BRAF wild-type unresectable stage III or IV melanoma | NIVO 1 mg/kg + IPI 3 mg/kg (N = 72) vs. IPI 3 mg/kg (N = 37) | ORR               | PFS                     |
| (Postow et al., 2015)  |                                 |                                               | NIVO + IPI                      |                   | NIVO + IPI              |
|                        |                                 |                                               | • 61% (95% CI = 49–72)          |                   | • Median, NR            |
|                        |                                 |                                               | • OR vs. IPI, 12.96 (95% CI = 3.91–54.49; p < .001) |                   | • HR vs. IPI, 0.40 (95% CI = 0.23–0.68; p < .001) |
|                        |                                 |                                               | IPI                             |                   |                         |
|                        |                                 |                                               | • 11% (95% CI = 3–25)           |                   |                         |

Note. FDA = U.S. Food and Drug Administration; NIVO = nivolumab; IPI = ipilimumab; PFS = progression-free survival; CI = confidence interval; HR = hazard ratio; ORR = objective response rate; OR = odds ratio; RCC = renal cell carcinoma; OS = overall survival; NR = not reached; NE = not evaluable; SUN = sunitinib; ITT = intention-to-treat; CRR = complete response rate; MSI-H = microsatellite instability-high; dMMR = mismatch repair; CRC = colorectal cancer; DCR = disease control rate; NSQ = nonsquamous; NSCLC = non-small cell lung cancer; carbo = carboplatin; cis = cisplatin; pembe = pembrolizumab; pembro = pembrolizumab; chemo = chemotherapy; DoR = duration of response; SQ = squamous; nab-pac = nanoparticle albumin-bound paclitaxel; pac = paclitaxel.  

*Table continued on the following page.*
Table 2. Clinical Efficacy of FDA-Approved Immuno-Oncology Combination Therapies (cont.)

| Study                  | Design                     | Tumor type                        | Interventions (N)          | Primary endpoints                                      | Key secondary endpoints       |
|------------------------|----------------------------|-----------------------------------|----------------------------|--------------------------------------------------------|-------------------------------|
| CheckMate 214 (Motzer et al., 2018) | Randomized, open-label, phase III study | Previously untreated intermediate- and poor-risk advanced clear-cell RCC | NIVO 3 mg/kg + IPI 1 mg/kg (N = 425) vs. SUN (N = 422) | OS (intermediate- and poor-risk) | OS (ITT) |
|                        |                            |                                   |                            | NIVO + IPI                                             | NIVO + IPI                     |
|                        |                            |                                   |                            | • Median, NR (95% CI = 28.2–NE) | • Median, NR (95% CI = 28.2–NE) |
|                        |                            |                                   |                            | • HR vs. SUN, 0.63 (99.8% CI = 0.44–0.89; p < .001) | • HR vs. SUN, 0.63 (99.8% CI = 0.44–0.89; p < .001) |
|                        |                            |                                   |                            | SUN Median, 26.0 mo (95% CI = 22.1–NE) | SUN Median, 26.0 mo (95% CI = 22.1–NE) |
|                        |                            |                                   |                            | • ORR (intermediate- and poor-risk) NIVO + IPI         | • ORR (intermediate- and poor-risk) NIVO + IPI |
|                        |                            |                                   |                            | • 42% (95% CI = 37–47) vs. SUN, p < .001 | • 42% (95% CI = 37–47) vs. SUN, p < .001 |
|                        |                            |                                   |                            | • 27% (95% CI = 22–31) | • 27% (95% CI = 22–31) |
|                        |                            |                                   |                            | CRR (intermediate- and poor-risk) NIVO + IPI         | CRR (intermediate- and poor-risk) NIVO + IPI |
|                        |                            |                                   |                            | • 9% vs. SUN, p < .001 | • 9% vs. SUN, p < .001 |
|                        |                            |                                   |                            | • 1% | • 1% |
|                        |                            |                                   |                            | PFS (intermediate- and poor-risk) NIVO + IPI         | PFS (intermediate- and poor-risk) NIVO + IPI |
|                        |                            |                                   |                            | • Median, 11.6 mo (95% CI = 8.7–15.5) | • Median, 11.6 mo (95% CI = 8.7–15.5) |
|                        |                            |                                   |                            | • HR vs. SUN, 0.82 (99.1% CI = 0.64–1.05; p = .03) | • HR vs. SUN, 0.82 (99.1% CI = 0.64–1.05; p = .03) |
|                        |                            |                                   |                            | SUN Median, 8.4 mo (95% CI = 7.0–10.8) | SUN Median, 8.4 mo (95% CI = 7.0–10.8) |
| CheckMate 142 (Overman et al., 2018) | Open-label, multicohort, phase II study | Previously treated MSI-H/dMMR metastatic CRC | NIVO 3 mg/kg + IPI 1 mg/kg (N = 119) | ORR | DCR (≥12 weeks) |
|                        |                            |                                   |                            | NIVO + IPI                                             | NIVO + IPI                     |
|                        |                            |                                   |                            | • 55% (95% CI = 45.2–63.8) | • 55% (95% CI = 45.2–63.8) |
|                        |                            |                                   |                            | SUN Median, 7.8 mo (95% CI = 6.5–10.2) | SUN Median, 7.8 mo (95% CI = 6.5–10.2) |

Note. FDA = U.S. Food and Drug Administration; NIVO = nivolumab; IPI = ipilimumab; PFS = progression-free survival; CI = confidence interval; HR = hazard ratio; ORR = objective response rate; OR = odds ratio; RCC = renal cell carcinoma; OS = overall survival; NR = not reached; NE = not evaluable; SUN = sunitinib; ITT = intention-to-treat; CRR = complete response rate; MSI-H = microsatellite instability-high; dMMR = mismatch repair; CRC = colorectal cancer; DCR = disease control rate; NSQ = nonsquamous; NSCLC = non-small cell lung cancer; carbo = carboplatin; cis = cisplatin; pem = pemetrexed; pembro = pembrolizumab; chemo = chemotherapy; DoR = duration of response; SQ = squamous; nab-pac = nanoparticle albumin-bound paclitaxel; pac = paclitaxel.
| Study               | Design                                      | Tumor type                                      | Interventions (N)                                      | Primary endpoints | Key secondary endpoints |
|---------------------|---------------------------------------------|-------------------------------------------------|--------------------------------------------------------|-------------------|-------------------------|
| KEYNOTE-189         | Randomized, double-blind, phase III study   | Previously untreated metastatic NSQ NSCLC       | Pembrolizumab 200 mg + carboplatin/cisplatin (N = 410) vs. carboplatin + pemetrexed (N = 206) | OS                | ORR                     |
|                     |                                             |                                                 |                                                        |                   | Pembrolizumab + chemo    |
|                     |                                             |                                                 |                                                        |                   | • Median, NR             |
|                     |                                             |                                                 |                                                        |                   | • HR vs. chemo, 0.49 (95% CI = 0.38-0.64; p < .001) |
|                     |                                             |                                                 |                                                        |                   | Chemo                   |
|                     |                                             |                                                 |                                                        |                   | • Median, 11.3 mo (95% CI = 8.7-15.1)                 |
|                     |                                             |                                                 |                                                        |                   | PFS                     |
|                     |                                             |                                                 |                                                        |                   | Pembrolizumab + chemo    |
|                     |                                             |                                                 |                                                        |                   | • Median, 8.8 mo (95% CI = 76-92)                      |
|                     |                                             |                                                 |                                                        |                   | Chemo                   |
|                     |                                             |                                                 |                                                        |                   | • HR vs. chemo, 0.52 (95% CI = 0.43-0.64; p < .001)   |
|                     |                                             |                                                 |                                                        |                   | Chemo                   |
|                     |                                             |                                                 |                                                        |                   | • Median, 4.9 mo (95% CI = 4.7-5.5)                    |
| KEYNOTE-021         | Randomized, open-label, phase II study      | Systemic therapy-naive stage IIIB or IV NSQ NSCLC | Pembrolizumab 200 mg + carboplatin + pemetrexed (N = 60) vs. carboplatin + pemetrexed (N = 63) | ORR               | OS                      |
|                     |                                             |                                                 |                                                        |                   | Pembrolizumab + chemo    |
|                     |                                             |                                                 |                                                        |                   | • 55% (95% CI = 42-68)                                   |
|                     |                                             |                                                 |                                                        |                   | • vs. chemo, p = .0016                                |
|                     |                                             |                                                 |                                                        |                   | Chemo                   |
|                     |                                             |                                                 |                                                        |                   | • 29% (95% CI = 18-41)                                   |
| KEYNOTE-407         | Randomized, double-blind, phase III study   | Previously untreated metastatic SQ NSCLC        | Pembrolizumab 200 mg + carboplatin/paclitaxel/nab-paclitaxel (N = 278) vs. paclitaxel/nab-paclitaxel (N = 281) | OS                | ORR                     |
|                     |                                             |                                                 |                                                        |                   | Pembrolizumab + chemo    |
|                     |                                             |                                                 |                                                        |                   | • Median, 15.9 mo (95% CI = 13.2-NR)                    |
|                     |                                             |                                                 |                                                        |                   | • HR vs. chemo, 0.64 (95% CI = 0.49-0.85; p < .001)    |
|                     |                                             |                                                 |                                                        |                   | Chemo                   |
|                     |                                             |                                                 |                                                        |                   | • Median, 11.3 mo (95% CI = 9.5-14.8)                   |
|                     |                                             |                                                 |                                                        |                   | PFS                     |
|                     |                                             |                                                 |                                                        |                   | Pembrolizumab + chemo    |
|                     |                                             |                                                 |                                                        |                   | • Median, 6.4 mo (95% CI = 6.2-8.3)                      |
|                     |                                             |                                                 |                                                        |                   | Chemo                   |
|                     |                                             |                                                 |                                                        |                   | • HR vs. chemo, 0.56 (95% CI = 0.45-0.70; p < .001)    |
|                     |                                             |                                                 |                                                        |                   | Chemo                   |
|                     |                                             |                                                 |                                                        |                   | • Median, 4.8 mo (95% CI = 4.3-5.7)                     |

Note. FDA = U.S. Food and Drug Administration; NIVO = nivolumab; IPI = ipilimumab; PFS = progression-free survival; CI = confidence interval; HR = hazard ratio; ORR = objective response rate; OR = odds ratio; RCC = renal cell carcinoma; OS = overall survival; NR = not reached; NE = not evaluable; SUN = sunitinib; ITT = intention-to-treat; CRR = complete response rate; MSI-H = microsatellite instability-high; dMMR = mismatch repair; CRC = colorectal cancer; DCR = disease control rate; NSQ = nonsquamous; NSCLC = non-small cell lung cancer; carb = carboplatin; cis = cisplatin; peme = pemetrexed; pembrol = pembrolizumab; chemo = chemotherapy; DoR = duration of response; SQ = squamous; nab-pac = nanoparticle albumin-bound paclitaxel; pac = paclitaxel.
Hoffner et al.  

Common any-grade IMARs in the combination group included diarrhea (45%), pruritus (36%), rash (30%), increased alanine aminotransferase (ALT; 19%), and hypothyroidism (17%). Grade 3 to 4 skin and subcutaneous, gastrointestinal (GI), endocrine, hepatic, pulmonary, and renal IMARs occurred more frequently with nivolumab plus ipilimumab than either monotherapy group (Wolchok et al., 2017).

In the CheckMate 069 trial of patients with previously untreated advanced melanoma, researchers reported IMARs (defined as select AEs of potentially immune-mediated cause) more frequently with nivolumab at 1 mg/kg plus ipilimumab at 3 mg/kg every 3 weeks than nivolumab alone. Common any-grade IMARs included diarrhea (45%), rash (42%), pruritus (35%), thyroid disorder (23%), colitis (23%), increased ALT (22%), and increased aspartate aminotransferase (AST; 21%), and occurred more frequently than with nivolumab alone. Grade 3 to 5 GI (21%), hepatic (15%), skin (10%), and endocrine (5%) IMARs occurred more frequently with nivolumab plus ipilimumab than nivolumab alone. Immunosuppressants were used in a higher percentage of patients receiving combination therapy (89% vs. 59%). The most commonly used systemic immunosuppressive agents across treatment groups were corticosteroids (82% vs. 50%, respectively), with topical agents used for dermatologic IMARs. Hormone replacement therapy was used to manage endocrine IMARs (Postow et al., 2015).

In a pooled analysis of patients with advanced melanoma treated with nivolumab at 1 mg/kg plus ipilimumab at 3 mg/kg every 3 weeks in CheckMate 067 and 069 and cohort 8 of the phase Ib open-label, dose-escalation CheckMate 004 study, IMARs, defined as AEs with immune-related etiology, were reported by 88% of patients (Sznol et al., 2017). Grade 3 to 4 IMARs occurred in 42% of patients, including hepatic (17%), GI (16%), and skin (7%) IMARs, with resolution rates of at least 79%, with the exception of immune-mediated endocrinopathies, which frequently required lifelong hormone replacement therapy (Sznol et al., 2017).

In CheckMate 214, in patients with previously untreated advanced RCC with a clear-cell component, grade 3 to 4 treatment-related AEs occurred less frequently with nivolumab at 3 mg/kg plus ipilimumab at 1 mg/kg every 3 weeks (46%) than sunitinib at 50 mg daily (63%; Motzer et al., 2018). Any-grade IMARs, defined as treatment-related select (immune-mediated) AEs, were reported in 80% of patients who received nivolumab plus ipilimumab. Of these, 35% received high-dose corticosteroids (≥ 40 mg of prednisone per day or equivalent; Motzer et al., 2018).

Among patients with MSI-H/dMMR metastatic CRC who received nivolumab at 3 mg/kg plus ipilimumab at 1 mg/kg every 3 weeks in CheckMate 142, any-grade IMARs, defined as select treatment-related AEs (events with potential immunologic etiology) included skin (29%), endocrine (25%), GI (23%), hepatic (19%), pulmonary (5%), and renal (5%) IMARs (Overman et al., 2018). Twenty-two percent (GI) to 56% (skin) of patients who experienced IMARs received immunosuppressive medication. Using protocol-specified management algorithms, IMARs resolved in 71% (skin) to 96% (GI) of patients, except for endocrine IMARs, which resolved in only 40% (Overman et al., 2018).

In KEYNOTE-189, 23% of patients with metastatic nonsquamous NSCLC who received pembrolizumab at 200 mg plus pemetrexed at 500 mg/m² and carboplatin AUC 5 mg/mL/min or cisplatin at 75 mg/m² every 3 weeks experienced IMARs, defined as immune-mediated AEs, vs. 12% of those who received chemotherapy alone (Gandhi et al., 2018). Common any-grade IMARs with combination therapy included hypothyroidism (7%), pneumonitis (4%), hyperthyroidism (4%), infusion reaction (3%), colitis (2%), and severe skin reaction (2%; Gandhi et al., 2018). Grade 3 to 5 IMARs occurred more often with pembrolizumab plus chemotherapy (9%) than chemotherapy alone (5%; Gandhi et al., 2018).

In the KEYNOTE-021 study of patients with advanced nonsquamous NSCLC, IMARs were defined as AEs of interest based on a presumed immunologic mechanism of action (Langer et al., 2016). The incidence of potential IMARs in the pembrolizumab at 200 mg plus pemetrexed at 500 mg/m² and carboplatin AUC 5 mg/mL/min every 3 weeks group of the as-treated population (22%) was greater than for chemotherapy alone...
Similar to KEYNOTE-189, common all-grade IMARs in patients who received pembrolizumab plus chemotherapy included hypothyroidism (15%), hyperthyroidism (8%), pneumonitis (5%), infusion reactions (3%), and severe skin reactions (2%); Langer et al., 2016. As with pembrolizumab plus chemotherapy in patients with NSCLC in KEYNOTE-189, most IMARs were grade 1 or 2 (85%) and manageable without treatment discontinuation (Langer et al., 2016).

In KEYNOTE-407, any-grade IMARs, defined as immune-mediated AEs, occurred in 29% of patients with metastatic squamous NSCLC who received pembrolizumab at 200 mg plus carboplatin AUC 6 mg/mL/min every 3 weeks and paclitaxel at 200 mg/m² or nab-paclitaxel at 100 mg/m² compared with 9% receiving chemotherapy alone (Paz-Ares et al., 2018). Common any-grade IMARs with combination therapy included hypothyroidism (8%), hyperthyroidism (7%), and pneumonitis (7%). Grade 3 to 5 IMARs were observed in 11% and 3% of patients, respectively, with immune-mediated pneumonitis leading to death in one patient in each group (Paz-Ares et al., 2018).

Table 3 summarizes incidences of any-grade IMARs and common grade 3 to 5 IMARs occurring in clinical trials of approved IO combination therapies, as well as proportions of patients who received immunosuppressive agents to manage IMARs. Although IMARs observed with IO combination therapy are the same as with IO mono-therapy, they occur more frequently, earlier, and potentially at a higher grade with IO combination therapy than IO monotherapy (Gandhi et al., 2018; Langer et al., 2016; Larkin et al., 2015; Madden & Hoffner, 2017; Postow et al., 2015; Weinstein et al., 2017). With prompt recognition and appropriate management, APPs can prevent potentially serious and/or life-threatening IMARs as well as unnecessary treatment discontinuations (Brahmer et al., 2018; Madden & Hoffner, 2017; Puzanov et al., 2017).

Advanced practice providers take on the role of clinicians, educators, and patient advocates, and their skills are most commonly utilized in the active treatment and management of cancer (Reynolds & McCoy, 2016). Nurse practitioners, physician assistants, and pharmacists collaborate with physicians to determine, prescribe, and deliver treatment; oversee care coordination between the patient and the patient’s providers; conduct new patient and follow-up visits; and provide treatment and symptom management (Bruinooge et al., 2018; Reynolds & McCoy, 2016). Oncology APPs in particular spend approximately 85% of their time providing direct patient care, with some even conducting genetic counseling and performing procedures (Bruinooge et al., 2018). Thus, oncology APPs are in a unique position to both educate patients with cancer receiving IO therapy to recognize IMARs early, and to appropriately manage IMARs and conduct follow-up care (Weinstein et al., 2017).

GUIDANCE FOR APPs TREATING PATIENTS RECEIVING IO COMBINATION THERAPY

- Advanced practice providers may explain to patients that they could receive IO/IO combination therapy and that although this IO combination approach may improve efficacy, it can also increase the risk for developing IMARs (Gandhi et al., 2018; Langer et al., 2016; Larkin et al., 2015; Postow et al., 2015; Wolchok et al., 2017).
- Advanced practice providers should be diligent in educating patients receiving IO combination therapy about the signs and symptoms of IMARs, whom to alert if they arise, and how they are managed. Early detection and management of IMARs are crucial to optimize clinical outcomes in these patients (Brahmer et al., 2018; Madden & Hoffner, 2017; Puzanov et al., 2017; Weinstein et al., 2017).
- Advanced practice providers should educate patients to immediately report any...
| Study                  | Tumor type                                      | Interventions (N) | Most common grade 3–5 IMARs in IO combination groups | Proportion of patients who required immunosuppressive agents to manage IMARs\(^a\) |
|-----------------------|------------------------------------------------|-------------------|----------------------------------------------------|----------------------------------------------------------------------------------|
| CheckMate 067         | Previously untreated unresectable stage III or IV melanoma | NIVO 1 mg/kg + IPI 3 mg/kg (N = 314) vs. NIVO 3 mg/kg (N = 316) vs. IPI 3 mg/kg (N = 315) | Diarrhea (10%) Increased ALT (9%) Colitis (8%) Increased AST (6%)                   | Use of immunosuppressive agents not reported                                      |
| CheckMate 069         | Previously untreated \(BRAF\) wild-type unresectable stage III or IV melanoma | NIVO 1 mg/kg + IPI 3 mg/kg (N = 94) vs. IPI 3 mg/kg (N = 46) | Colitis (17%) Diarrhea (11%) Increased ALT (11%) Increased AST (7%) Rash (5%)         | Immunosuppressive agents\(^b\) NIVO + IPI: 89% IPI: 59%                           |
| CheckMate 214         | Previously untreated intermediate- and poor-risk advanced clear-cell RCC | NIVO 3 mg/kg + IPI 1 mg/kg (N = 547) vs. SUN (N = 535) | Data of IMARs by grade not reported\(^c\) | Corticosteroids NIVO + IPI: 82% IPI: 50%                                           |
| CheckMate 142         | Previously treated \(MSI-H/dMMR\) metastatic CRC | NIVO 3 mg/kg + IPI 1 mg/kg (N = 119) | Hepatic (11%) Endocrine (5%) Dermatologic (4%) GI (3%) | Use of immunosuppressive agents not reported                                      |
| KEYNOTE-189           | Previously untreated metastatic NSQ NSCLC      | Pembro 200 mg + carbo/cis + peme (N = 405) vs. carbo + peme (N = 202) | Pneumonitis (3%) Severe skin reaction (2%) Nephritis (1%) Hepatitis (1%) | Use of immunosuppressive agents not reported                                      |
| KEYNOTE-021           | Chemotherapy-naive stage IIIIB or IV NSQ NSCLC | Pembro 200 mg + carbo + peme (N = 59) vs. carbo + peme (N = 62) | Pneumonitis (2%) Infusion reactions (2%) Severe skin reaction (2%)                 | Use of immunosuppressive agents not reported                                      |
| KEYNOTE-407           | Previously untreated metastatic SQ NSCLC      | Pembro 200 mg + carbo + pac/nab-pac (N = 278) vs. pac/nab-pac (N = 281) | Pneumonitis (3%) Colitis (2%) Hepatitis (2%) Infusion reaction (1%) Severe skin reaction (1%) | Use of immunosuppressive agents not reported                                      |

Note. Hormone-replacement therapy was used to manage endocrine IMARs. FDA = U.S. Food and Drug Administration; IMAR = immune-mediated adverse reaction; IO = immuno-oncology; NIVO = nivolumab; IPI = ipilimumab; ALT = alanine aminotransferase; AST = aspartate aminotransferase; RCC = renal cell carcinoma; SUN = sunitinib; MSI-H = microsatellite instability-high; dMMR = defective DNA mismatch repair; CRC = colorectal cancer; GI = gastrointestinal; NSQ = nonsquamous; NSCLC = non-small cell lung cancer; pembro = pembrolizumab; carbo = carboplatin; cis = cisplatin; peme = pemetrexed; SQ = squamous; pac = paclitaxel; nab-pac = nanoparticle albumin-bound paclitaxel.\(^a^\) Immunosuppressive agents include systemic, topical steroidal agents, and secondary immunosuppressive medications (e.g., infliximab).\(^b^\) Of the 547 previously untreated patients with advanced clear-cell RCC treated with nivolumab plus ipilimumab in CheckMate 214, 436 (79.7%) patients experienced treatment-related select (immune-mediated) adverse events.\(^c^\) High-dose corticosteroids (≥ 40 mg of prednisone per day or equivalent).
health status changes or AE symptoms and support them throughout the treatment trajectory (Brahmer et al., 2018; Madden & Hoffner, 2017)

• Patient status and potential symptoms should be evaluated regularly (Brahmer et al., 2018; Madden & Hoffner, 2017)

• If an IMAR is suspected, APPs should have a low threshold for obtaining a subspecialty consultation urgently as well as for admitting patients to the hospital for closer monitoring and more intensive treatment if necessary (Brahmer et al., 2018; Puzanov et al., 2017).

**IMAR Frequency, Presentation, and Recognition**

To provide the most effective support to patients, it is important that oncology APPs understand the differences in IMAR frequencies between monotherapy and combination therapy and between individual ICIs, and their presentation, time to onset, and management (Weinstein et al., 2017).

Immune-mediated adverse reactions are common for all ICIs and across different tumor types: Events of any grade were reported in 11% to 49% of patients treated with anti–PD-1 or anti–PD-L1 monotherapy and 61% to 64% of those receiving anti–CTLA-4 monotherapy (Brahmer et al., 2012; Gulley et al., 2017; Hodi et al., 2010; Pillai et al., 2018; Reck et al., 2016; Tarhini, 2013; Topalian et al., 2012). Immune-mediated adverse reactions were also observed in up to 80% of patients treated with IO/IO combination therapy (Motzer et al., 2018). For combined pembrolizumab/chemotherapy, rates of IMARs ranged from 22% to 32%, compared with 5% to 14% of patients treated with chemotherapy alone (Gandhi et al., 2018; Langer et al., 2016; Nyberg, 2018; Reck et al., 2016; Zhou et al., 2018).

Overall, the most common IMARs associated with IO therapy are those affecting the skin and endocrine, GI (including liver), musculoskeletal, and respiratory systems (Figure 2; Puzanov et al., 2017). However, IMARs can affect any organ system; less common but very impactful IMARs include neurologic, ocular, cardiovascular, hematologic, and renal IMARs (Puzanov et al., 2017). Diverse patterns of IMAR classification and severity exist between IO classes (Khoja, Day, Wei-Wu Chen, Siu, & Hansen, 2017; Puzanov et al., 2017). For example, colitis, hypophysitis, rash, and pruritus IMARs are more commonly associated with anti–CTLA-4 antibodies, whereas pneumonitis, arthralgia, hypothyroidism, and vitiligo are more common with anti–PD-1 antibodies (Khoja et al., 2017). Notably, CTLA-4 inhibitors are more likely than PD-1 inhibitors to induce IMARs (Kartolo, Sattar, Sahai, Baetz, & Lakoff, 2018; Khoja et al., 2017).

Patients receiving IO/IO combinations develop similar types of IMARs as with IO monotherapy, whereas adverse reactions in patients receiving IO/chemotherapy combinations are re-
lated to both IO and chemotherapy agents (Gandhi et al., 2018; Paz-Ares et al., 2018; Wolchok et al., 2017). In patients receiving IO/chemotherapy combinations, IMARs related to ICIs may present similarly to those with chemotherapy (e.g., diarrhea and colitis) but may have very different causes and, therefore, require different diagnostic procedures, additional workup, and distinct management. As a result of pharmacodynamic differences, IMARs may present later and last longer than AEs related to chemotherapy (Puzanov et al., 2017).

Immune-mediated adverse reactions related to IO therapy can affect any organ system, and because more than one organ may be affected, APPs need to consider all organs in their differential IMAR diagnosis (Madden & Hoffner, 2017; Puzanov et al., 2017). The signs and symptoms of IMARs, such as immune-mediated pneumonitis, hepatitis, and hematologic AEs, may present similarly to cancer progression (Champiat et al., 2016; Puzanov et al., 2017).

**IMAR Time to Onset**
Although IMARs most often occur within 3 to 6 months of IO initiation, some IMARs occur earlier (e.g., after one infusion) or later, even after treatment has been discontinued (Champiat et al., 2017; Madden & Hoffner, 2017; Michot et al., 2016). Importantly, IMARs associated with IO combination therapies tend to have an earlier onset and are more severe compared with IO monotherapy (Madden & Hoffner, 2017). For instance, grade 3 to 4 GI IMARs in patients receiving nivolumab plus ipilimumab occur at a median of 74 weeks (range, 1.0–48.9) after initiation of IO combination therapy compared to a median of 26.3 weeks (range, 13.1–57.0) in patients receiving nivolumab monotherapy (Haanen et al., 2017).

**IMAR Management**
The American Society of Clinical Oncology (ASCO), in collaboration with the National Comprehensive Cancer Network (NCCN), and the Society for Immunotherapy of Cancer (SITC) have published multidisciplinary guidelines and treatment algorithms that are available to APPs to assist in recognizing and managing IMARs (Brahmer et al., 2018; Puzanov et al., 2017). These guidelines focus on the recognition and management of a wide array of IMARs by organ system, including asymptomatic or mild cases in addition to less frequent toxicities not discussed in this review. They also provide recommendations for additional evaluations, interrupting or permanently discontinuing ICI treatment, dosing of corticosteroid therapy, and alternative immunosuppressive therapies (Brahmer et al., 2018; Puzanov et al., 2017).

ASCO/NCCN guidelines are summarized in Table 4 (Brahmer et al., 2018). The management of IMARs relies heavily on early intervention with corticosteroids and other immunomodulatory agents, such as infliximab, which should be considered secondary to corticosteroids in order to reduce the potential for short- and long-term complications (Puzanov et al., 2017). Patients who experience immune-mediated endocrinopathies, such as adrenal insufficiency, hypothyroidism, and type 1 diabetes mellitus, commonly require lifelong hormonal replacement or antidiabetic medication, as immune-mediated endocrinopathies are typically irreversible (Brahmer et al., 2018; Champiat et al., 2016; Puzanov et al., 2017). Advanced practice providers should advise all patients who experience adrenal insufficiency to obtain and carry a medical alert bracelet (Puzanov et al., 2017).

With the exception of some neurologic, hematologic, and cardiac toxicities, ASCO/NCCN guidelines generally recommend ICI therapy be continued with careful monitoring for grade 1 toxicities (Brahmer et al., 2018). In contrast, ICIs should be withheld for most grade 2 toxicities, and patients may receive corticosteroids (initial dose of 0.5 to 1 mg/kg/day of prednisone or equivalent; Brahmer et al., 2018). Advanced practice providers should consider resuming ICI therapy withheld for grade 2 toxicities when symptoms and/or laboratory values revert to grade 1 or less (on daily prednisone equivalents of ≤ 10 mg; Brahmer et al., 2018).

Immune checkpoint inhibitors should also be withheld for patients with grade 3 IMARs, who should receive high-dose corticosteroids (prednisone at 1 to 2 mg/kg/day or methylprednisolone IV at 1 to 2 mg/kg/day; Brahmer et al., 2018). ASCO/NCCN guidelines recommend tapering corticosteroids over the course of at least 4 to 6
weeks (Brahmer et al., 2018). If symptoms do not improve with 48 to 72 hours of high-dose corticosteroids, secondary immune-modulating treatment with infliximab, mycophenolate mofetil, azathioprine, or cyclophosphamide may be offered for some toxicities (Brahmer et al., 2018). Vedolizumab may be considered in patients experiencing immune-mediated colitis refractory to infliximab and/or contraindicated to tumor necrosis factor alpha (TNF-α) inhibitors (Brahmer et al., 2018). Advanced practice providers should be aware that infliximab may cause liver failure and might not be appropriate for patients experiencing immune-mediated hepatitis (Brahmer et al., 2018; Janssen Biotech, 2017). Infliximab has also been associated with heart failure, and should be avoided in patients with moderate-to-severe heart failure (Page et al., 2016).

When symptoms and/or laboratory values of grade 3 toxicities revert to grade 1 or less in patients initially receiving IO/IO combination therapy, resuming IO therapy may be offered to the patient, most commonly as anti–PD-(L)1 monotherapy. However, APPs should use caution when rechallenging patients, especially those who developed early-onset IMARs during initial ICI therapy (Brahmer et al., 2018). Dose adjustments, such as lowering the dose of ICI treatment, are not recommended (AstraZeneca UK Limited, 2018; Brahmer et al., 2018; Bristol-Myers Squibb, 2018, 2019; EMD Serono Inc, 2018; Genentech, 2019; Merck & Co Inc, 2019; Regeneron Pharmaceuticals Inc and sanofi-aventis US LLC, 2019), and in general, ICI therapy should be permanently discontinued for grade 4 IMARs with the exception of endocrinopathies controlled by hormone replacement therapy (Brahmer et al., 2018). Because dose modifications (i.e., withholding or permanently discontinuing ICI therapy) vary by IMAR, grade of severity, and drug, APPs should refer to up-to-date prescribing information for each ICI and/or multidisciplinary guidelines for appropriate dose modifications (AstraZeneca UK Limited, 2018; Brahmer et al., 2018; Bristol-Myers Squibb, 2018, 2019; EMD Serono Inc, 2018; Genentech, 2019; Haanen et al., 2017; Merck & Co Inc, 2019; Puzanov et al., 2017; Regeneron Pharmaceuticals Inc and sanofi-aventis US LLC, 2019).

Immune-mediated adverse reaction treatment should be tailored to each patient’s medical history; comorbidities; underlying disease status; type, number, and severity of AEs; ICI administered; and ability to tolerate corticosteroids (Puzanov et al., 2017). Treating IMARs in patients with existing comorbidities can be challenging because practice guidelines and established guidelines often utilize evidence from clinical trials in which patients with multiple chronic conditions, including those with autoimmune disorders and transplant recipients, may be excluded (Brahmer et al., 2018). Advanced practice providers must take into account the complexity and uncertainty created

| IMAR grade | Recommendation |
|------------|----------------|
| 1          | In general, continue ICIs with close monitoring for grade 1 toxicities, with the exception of some neurologic, hematologic, and cardiac toxicities |
| 2          | Hold ICIs for most grade 2 toxicities and consider resuming when symptoms and/or laboratory values revert to ≤ grade 1 Corticosteroids (initial dose of 0.5 to 1 mg/kg/day of prednisone or equivalent) may be administered |
| 3          | Hold ICIs for grade 3 toxicities and initiate high-dose corticosteroids (prednisone 1 to 2 mg/kg/day or methylprednisolone IV 1 to 2 mg/kg/day) Taper corticosteroids over the course of at least 4 to 6 weeks If symptoms do not improve within 48 to 72 hours of high-dose corticosteroids, infliximab may be offered for some toxicities |
| 4          | In general, permanently discontinue ICIs for grade 4 toxicities (with the exception of endocrinopathies that have been controlled by hormone replacement) |

Note. ICI = immune checkpoint inhibitor. Information from Brahmer et al. (2018).
by the presence of comorbidities when developing any treatment plan. Advanced practice providers should review all chronic conditions present in the patient and take them into account when formulating management and follow-up plans for patients who develop IMARs on IO therapy (Brahmer et al., 2018; Puzanov et al., 2017). Before initiating IO therapies in transplant recipients or patients with comorbid autoimmune disorders, APPs should thoroughly discuss potential risks and benefits with the patient (Boils, Aljadir, & Cantafio, 2016; Brahmer et al., 2018).

Best practice lessons related to IO combination therapy management may be transferable between tumor types. The IO landscape is changing rapidly, with many new agents in development for multiple tumor types (Tang, Shalabi, & Hubbard-Lucey, 2018). The recognition and appropriate management of IMARs are similar regardless of tumor type (AstraZeneca UK Limited, 2018; Bristol-Myers Squibb, 2018, 2019; EMD Serono Inc, 2018; Genentech, 2019; Merck & Co Inc, 2019; Regeneron Pharmaceuticals Inc and sanofi-aventis US LLC, 2019). As research in immune-system activation and suppression advances and more data are made available, APPs need to stay abreast of these developments to enrich their understanding and appropriate management of IMARs as they evolve (Bertrand, Kostine, Barnetche, Truchetet, & Schaeverbeke, 2015; Khoja et al., 2017; Puzanov et al., 2017).

**CLINICAL VIGNETTE**

Patient LL (weight, 60 kg) was diagnosed with **BRAF** wild-type stage IV metastatic melanoma. (This clinical vignette was developed based on clinical practice and not approved indications.) Her medical oncologist prescribed IO combination therapy, consisting of nivolumab at 1 mg/kg and ipilimumab at 3 mg/kg every 3 weeks for four doses or until unacceptable toxicity, followed by nivolumab at 480 mg every 4 weeks.

At week 6, patient LL reported having five large-volume watery stools (baseline one bowel movement per day) and was evaluated by her APP. Upon physical examination, a stat chemistry panel, complete blood count, and a stool evaluation for **Campylobacter**, **Salmonella**, **Clostridium difficile**, ova, and parasites were obtained. Nivolumab and ipilimumab were withheld per ASCO/NCCN guidelines because of suspected grade 2 immune-mediated colitis, and patient LL was monitored closely by the APP (Brahmer et al., 2018).

Patient LL was given an initial 30-mg dose of IV methylprednisolone and started on prednisone at 30 mg twice daily (1 mg/kg/day), to be taken with food, until symptoms resolved to grade 1, and was given the option to start an H$_2$-receptor antagonist or a proton pump inhibitor to minimize the risk for heartburn, GI bleeding, and ulcerations associated with steroid use. The APP educated patient LL on the side effects of corticosteroids, including irritability, increased appetite, and difficulty sleeping. A prednisone taper over the course of 6 weeks was planned upon resolution of symptoms to grade 0 or 1. A low fiber, low residual diet and an oral hydration plan were recommended. Education concerning IO–induced colitis and IO untoward side effects were again provided to patient LL and the approved caregiver. Both the patient and caregiver were counseled to be aware of and inform the APP if abdominal pain, nausea, cramping, blood or mucus in the stool, changes in bowel habits, fever, abdominal distention, obstipation, or constipation occurred, and they were urged to report a worsening of any untoward side effect immediately. The patient and caregiver understood the instructions and were able to correctly repeat them back to the APP.

Patient LL was monitored closely with daily telephone calls by the APP for assessment of diarrhea symptoms, as well as overall health status. All stool cultures were negative when patient LL returned 3 days later for further examination. However, diarrheal symptoms had not improved, with bowel movements increasing to eight times per day. The patient was admitted to the hospital and corticosteroid treatment changed to IV methylprednisolone at 60 mg twice daily (2 mg/kg/day).

Diarrheal symptoms persisted 48 hours after initiating IV corticosteroids. IV infliximab at 300 mg (5 mg/kg) was therefore administered as a single dose, and the patient was monitored for hypersensitivity reaction, liver enzyme elevation, infections, and cytopenia. Diarrheal symptoms subsided over the following week and recovered to grade 1. Per ASCO/NCCN guidelines, ipilimumab was permanently discontinued and nivolu-
mab monotherapy was initiated at 480 mg every 4 weeks (Brahmer et al., 2018). The APP followed patient LL closely for potential IMARs during nivolumab monotherapy; colitis did not recur.

**FUTURE DIRECTIONS**

New ICI combination therapies are being evaluated in clinical trials and have demonstrated clinical activity and tolerability in multiple tumor types. The clinical activity and safety/tolerability of nivolumab, an anti–PD-1 antibody, in combination with relatlimab, an anti–lymphocyte-activation gene 3 (LAG-3) antibody, are being assessed in a cohort of patients with metastatic and/or unresectable melanoma who received prior IO therapy in a phase I/IIa study (Ascierto et al., 2017). Of 48 evaluable patients, 13% achieved a response and approximately 31% had a reduction in tumor burden from baseline at a median follow-up of 14 weeks (Ascierto et al., 2017). The safety profile of relatlimab plus nivolumab was comparable to that of nivolumab monotherapy (Ascierto et al., 2017). In the prior IO melanoma cohort (n = 55), the most common any-grade AEs were diarrhea and nausea (in 5% each; Ascierto et al., 2017).

The anti–PD-1 antibody durvalumab is being evaluated in combination with the anti–CTLA-4 antibody tremelimumab in various advanced tumor types, including NSCLC, urothelial carcinoma, and squamous cell carcinoma of the head and neck (Antonia et al., 2016; Balar et al., 2018; Siu et al., 2018). In a phase Ib study that evaluated durvalumab plus tremelimumab in patients with locally advanced or metastatic NSCLC who had no prior immunotherapy, the authors concluded that frequencies of AEs, as well as proportions of patients receiving immunomodulatory agents (e.g., topical steroids) and immunosuppressive agents (e.g., infliximab) were broadly comparable with those in a phase III trial of previously untreated patients with advanced melanoma who received nivolumab plus ipilimumab (Antonia et al., 2016; Larkin et al., 2015).

**CONCLUSION**

As meaningful partners on a multidisciplinary cancer-care team, APPs play a vital role in treating patients with cancer, especially those receiving IO combination therapy with ICIs. Because IMARs frequently occur with IO/IO and IO/chemotherapy combination therapies, APPs have a unique opportunity to appropriately educate patients. Recipients of these therapies need to learn from their APPs about the possibility of IMARs, and how to identify and manage them in order to reduce the risk of short- and long-term complications; remain on IO therapy; and ultimately experience improved clinical outcomes.

**Acknowledgment**

Medical writing support and editorial assistance were provided by Jason Hoffman, PharmD, RPh, Katie Groschwitz, PhD, and Jay Rathi, MA, of Spark Medica Inc, and were funded by Bristol-Myers Squibb, according to Good Publication Practice 3 guidelines.

**Disclosure**

Ms. Hoffner has served on the advisory board for Bristol-Myers Squibb and Merck. Ms. Vaughn has no conflicts of interest to disclose. Ms. Reed has served on speakers bureaus and advisory boards for Array BioPharma and Bristol-Myers Squibb, the advisory board for Pfizer, and speakers bureaus for Genentech, Merck, Novartis, and Taiho. Ms. Weber has served as a speaker for Bristol-Myers Squibb.

**References**

Antonia, S. J., Goldberg, S. B., Balmanoukian, A., Chaft, J. E., Sanborn, R. E., Gupta, A.,...Gu, Y. (2016). Safety and antitumour activity of durvalumab plus tremelimumab in non-small-cell lung cancer: A multicentre, phase 1b study. *Lancet Oncology, 17*(3), 299–308. https://doi.org/10.1016/S1470-2045(15)00544-6

Antonia, S. J., Larkin, J., & Ascierto, P. A. (2014). Immuno-oncology combinations: A review of clinical experience and future prospects. *Clinical Cancer Research, 20*(24), 6258–6268. https://doi.org/10.1158/1078-0432.CCR-14-1457

Antonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P.,...Calvo, E. (2016). Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial. *Lancet Oncology, 17*(7), 883–895. https://doi.org/10.1016/S1470-2045(16)30098-5

Aoto, K., Mimura, K., Okayama, H., Saito, M., Chida, S., Noda, M.,...Kono, K. (2018). Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma. *Oncology Reports, 39*(1), 151–159. https://doi.org/10.3892/or.2017.6097

Apetoh, L., Ladoire, S., Coukos, G., & Ghiringhelli, F. (2015). Combining immunotherapy and anticancer agents: The right path to achieve cancer cure? *Annals of Oncol-*
AstraZeneca UK Limited. (2018). Imfinzi (durvalumab) pack - Ascierto, P. A., Bhatia, S., Bono, P., Sanborn, R. E., Lipson, E. J., Callahan, M. K.,...Curigliano, G. (2017). Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab in patients with melanoma previously treated with anti–PD-1/PD-L1 therapy [Abstract 9520]. Journal of Clinical Oncology (ASCO Annual Meeting Abstracts), 35(Suppl). https://doi.org/10.1200/JCO.2017.35.15_suppl.9520

AstraZeneca UK Limited. (2018). Imfinzi (durvalumab) package insert. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761069s000lbl.pdf

Balar, A. V., Mahipal, A., Grande, E., Villalobos, V. M., Salas, S., Kang, T. W., Van der Heijden, M. S. (2018). Abstract CT112: Durvalumab + tremelimumab in patients with metastatic urothelial cancer. Cancer Research, 78(13 supplement). https://doi.org/10.1158/1538-7445.Am2018-ct112

Bertrand, A., Kostine, M., Barnetche, T., Truchetet, M. E., & Schaeverbeke, T. (2015). Immune related adverse events associated with anti-CTLA-4 antibodies: Systematic review and meta-analysis. BMC Medicine, 13, 211. https://doi.org/10.1186/s12916-015-0455-8

Boils, C. L., Aljadir, D. N., & Canfario, A. W. (2016). Use of the PD-1 pathway inhibitor nivolumab in a renal transplant patient with malignancy. American Journal of Transplantation, 16(8), 2496–2497. https://doi.org/10.1111/ajt.13786

Brahmer, J. R., Latchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M.,...Thompson, J. A. (2018). Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 36(17), 1714–1768. https://doi.org/10.1200/JCO.2017.77.6385

Brahmer, J. R., Tykodi, S. S., Chow, L. Q., Hwu, W. J., Topalian, S. L., Hwu, P., Wigginton, J. M. (2012). Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New England Journal of Medicine, 366(26), 2455–2465. https://doi.org/10.1056/NEJMoa1200694

Bristol-Myers Squibb. (2018). Yervoy (ipilimumab) package insert. https://packageinserts.bms.com/pi/pi_yervoy.pdf.

Bristol-Myers Squibb. (2019). Opdivo (nivolumab) package insert. https://packageinserts.bms.com/pi/pi_opdivo.pdf.

Bruijnooge, S. S., Pickard, T. A., Vogel, W., Hanley, A., Schenkkel, C., Garrett-Mayer, E.,...Williams, S. F. (2018). Understanding the role of advanced practice providers in oncology in the United States. Journal of Oncology Practice, 14(9), e518–e532. https://doi.org/10.1200/JOP.18.00181

Champiat, S., Lambotte, O., Barreau, E., Belkhir, R., Berdelou, A., Carbonnel, F.,...Marabelle, A. (2016). Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper. Annals of Oncology, 27(4), 559–574. https://doi.org/10.1093/annonc/mdv623

Chaudhari, P. B. (2017). Nivolumab - pearls of evidence. Indian Journal of Medical and Paediatric Oncology, 38(4), 520–525. https://doi.org/10.4103/ijmpo.ijmpo_193.16

EMD Serono Inc. (2018). Bavencio (avelumab) package insert. https://www.emdserono.com/content/dam/web/corporate/non-images/country-specifics/us/pi/bavencio-pi.pdf.

Gandhi, L., Rodriguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F.,...Powell, S. F. (2018). Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. New England Journal of Medicine, 378, 2078–2092. https://doi.org/10.1056/NEJMoa1801005

Genentech. (2019). Tecentriq (atezolizumab) package insert. https://www.gene.com/download/pdf/tecentriq_prescribing.pdf

Grabosch, S., Zeng, F., Zhang, L., Strange, M., Brozick, J., Edwards, R. P., & Vlad, A. (2015). PD-L1 biology in response to chemotherapy in vivo and in vitro in ovarian cancer. Journal for ImmunoTherapy of Cancer, 3(suppl 2), P302. https://doi.org/10.1186%2F2051-1426-3-S2-P302

Gulley, L. J., Rajan, A., Spigel, D. R., Iannotti, N., Chandler, J., Wong, D. J. L.,...Kelly, K. (2017). Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): Dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncology, 18(5), 599–610. https://doi.org/10.1016/S1470-2045(17)30240-1

Haenen, J. B., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017). Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 28(suppl 4), iv119–iv142. https://doi.org/10.1093/annonc/mdx225

Hodi, F. S., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Rutkowski, P., Cowey, C. L.,...Wolchok, J. D. (2018). Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncology, 19(11), 1480–1492. https://doi.org/10.1016/S1470-2045(18)30700-9

Hodi, F. S., O’Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haenen, J. B.,...Urba, W. J. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 363(8), 711–723. https://doi.org/10.1056/NEJMoa1003466

Janssen Biotech. (2017). Remicade (infliximab) package insert. http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/REMICADE-pi.pdf.

Kartolo, A., Sattar, J., Sahai, V., Baetz, T., & Laffo, J. M. (2018). Predictors of immunotherapy-induced immune-related adverse events. Current Oncology, 25(S), e403–e410. https://doi.org/10.3747/co.25.4.6.3

Khoja, L., Day, D., Wei-Wu Chen, T., Siu, L. L., & Hansen, A. R. (2017). Tumour- and class-specific patterns of immune-related adverse events. Current Oncology, 25(5), e403–e410. https://doi.org/10.3747/co.25.4.7

Langer, C. J. (2015). Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): The role of immune checkpoint inhibitors: A systematic review. Annals of Oncology, 26(10), 2377–2385. https://doi.org/10.1093/annonc/mdx286

Kreamer, K. M. (2014). Immune checkpoint blockade: A new paradigm in treating advanced cancer. Journal of the Advanced Practitioner in Oncology, 5(6), 418–431. https://doi.org/10.1007/s10619-014-0563-5

Kreamer, K. M. (2014). Immune checkpoint blockade: A new paradigm in treating advanced cancer. Journal of the Advanced Practitioner in Oncology, 5(6), 418–431. https://doi.org/10.1007/s10619-014-0563-5

Langer, C. J. (2015). Emerging immune check-point inhibitors in the role of immune checkpoint inhibitors. American Journal of Clinical Oncology, 38(4), 422–430. https://doi.org/10.1097/COC.0000000000000095

Langer, C. J., Gadgeel, S. M., Borghaei, H., Padresmitrakopoulou, V. A., Patnaik, A., Powell, S. F.,...Panwalkar, A. (2016). Carboplatin and pemetrexed with or without pembrolizumab for advanced non-squamous non-small-cell lung
cancer: A randomised, phase 2 cohort of the open-label KEYNOTE-021 study. *Lancet Oncology*, 17(11), 1497–1508. https://doi.org/10.1016/S1470-2045(16)30498-3

Larkin, J., Chiariolone-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D.,...Wolchok, J. D. (2015). Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. *New England Journal of Medicine*, 373(3), 23–34. https://doi.org/10.1056/NEJMoa1504030

Madden, K. M., & Hoffner, B. (2017). Ipilimumab-based therapy: Consensus statement from the faculty of the melanoma nursing initiative on managing adverse events with ipilimumab monotherapy and combination therapy with nivolumab. *Clinical Journal of Oncology Nursing*, 21(suppl 4), 30–41. https://doi.org/10.1188/17CJON.S4.30-41

Merck & Co Inc. (2019). Keytruda (pembrolizumab) package insert. https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf.

Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S.,...Lambotte, O. (2016). Immune-related adverse events with immune checkpoint blockade: A comprehensive review. *European Journal of Cancer*, 54, 139–148. https://doi.org/10.1016/j.ejca.2015.11.016

Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K.,...Pawles, T. (2018). Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. *New England Journal of Medicine*, 378(4), 1277–1290. https://doi.org/10.1056/NEJMoa1712126

Nybø, K. (2018). Immunotherapy succeeds in squamous NSCLC, establishing a new frontline standard of care. *IASLC Lung Cancer News*. Retrieved from https://www.lungcancernews.org/2018/08/28/immunotherapy-succeeds-in-squamous-nsclc-establishing-a-new-frontline-standard-of-care/

Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H. J., Gelsomino, F., Aglietta, M.,...André, T. (2018). Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. *Journal of Clinical Oncology*, 36(8), 773–779. https://doi.org/10.1200/JCO.2017.76.9901

Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H. J., Morse, M. A.,...André, T. (2017). Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study. *Lancet Oncology*, 18(9), 1182–1191. https://doi.org/10.1016/S1470-2045(17)30422-9

Page, R. L., O’Bryant, C. L., Cheng, D., Dow, T. J., Ky, B., Stein, C. M.,...Lindendiff, J. (2016). Drugs that may cause or exacerbate heart failure: A scientific statement from the American Heart Association. *Circulation*, 134(6), e32–e69. https://doi.org/10.1161/CIR.0000000000000426

Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gumus, M., Mazieres, J.,...Kowalski, D. M. (2018). Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. *New England Journal of Medicine*, 379(21), 2040–2051. https://doi.org/10.1056/NEJMoa1810865

Peng, J., Hamanishi, J., Matsumura, N., Abiko, K., Murat, K., Baba, T.,...Mandai, M. (2015). Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-kB to foster an immunosuppressive tumor microenvironment in ovarian cancer. *Cancer Research*, 75(23), 5034–5045. https://doi.org/10.1158/0008-5472.CAN-14-3098

Pillai, R. N., Behera, M., Owonikoko, T. K., Kamphorst, A. O., Pakkala, S., Belani, C. P.,...Ramalingam, S. S. (2018). Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. *Cancer*, 124(2), 271–277. https://doi.org/10.1002/cncr.31043

Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D. F.,...Giguere, J. K. (2015). Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. *New England Journal of Medicine*, 372(21), 2006–2017. https://doi.org/10.1056/NEJMoa144428

Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018). Immune-related adverse events associated with immune checkpoint blockade. *New England Journal of Medicine*, 378(2), 158–168. https://doi.org/10.1056/NEJMra1703481

Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., 3rd, Brogdon, C., Dadu, R.,...Ernstoff, M. S. (2017). Managing toxicities associated with immune checkpoint inhibitors: consensuses recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. *Journal for ImmunoTherapy of Cancer*, 5(1), 95. https://doi.org/10.1186/s40425-017-0300-z

Reck, M., Rodriguez-Abreu, D., Robinson, A. G., Hui, R., Coszó, T., Pulop, A.,...Brahmer, J. R. (2016). Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. *New England Journal of Medicine*, 375(19), 1823–1833. https://doi.org/10.1056/NEJMoa1606774

Regeron Pharmaceuticals Inc and sanofi-aventis US LLC. (2019). Libtayo (cemiplimab-rwlc) package insert. Retrieved from https://www.regeron.com/sites/default/files/Libtayo_FPI.pdf

Reynolds, R. B., & McCoy, K. (2016). The role of advanced practice providers in interdisciplinary oncology care in the United States. *Chinese Clinical Oncology*, 5(3), 44. https://doi.org/10.21037/cco.2016.05.01.

Siu, L. L., Even, C., Mesia, R., Remenar, E., Daste, A., Delord, J. P.,...Fayette, J. (2018). Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low/negative recurrent or metastatic HNSCC: The phase 2 CONDOR randomized clinical trial. *JAMA Oncology*, 5(2), 195–203. https://doi.org/10.1001/jamaoncol.2018.4628

Sznol, M., Ferrucci, P. F., Hogg, D., Atkins, M. B., Wolter, P., Guidoboni, M.,...Wolchok, J. D. (2017). Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. *Journal of Clinical Oncology*, 35(34), 3815–3822. https://doi.org/10.1200/JCO.2016.72.1167

Tang, J., Shalabi, A., & Hubbard-Lucey, V. M. (2018). Comprehensive analysis of the clinical immuno-oncology landscape. *Annals of Oncology*, 29(1), 84–91. https://doi.org/10.1093/annonc/mdx755

Tarhini, A. (2013). Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: The underlying mechanisms and clinical management. *Scientifica* (Cairo), 2013, Article ID 857519. https://doi.org/10.1155/2013/857519

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gethering, S. N., Smith, D. C., McDermott, D. F.,...Sznol, M. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in
Weinstein, A., Gordon, R.-A., Kasler, M. K., Burke, M., Ranjan, S., Hodgetts, J.,...Shames, Y. (2017). Understanding and managing immune-related adverse events associated with immune checkpoint inhibitors in patients with advanced melanoma. *Journal of the Advanced Practitioner in Oncology, 8*(1), 58–72. https://doi.org/10.6004/jadpro.2017.8.1.5

Weintraub K. (2013). Drug development: Releasing the brakes. *Nature, 504*(7480), S6–S8. https://doi.org/10.1038/504S6a

Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J. J., Cowey, C. L.,...Ferrucci, P. F. (2017). Overall survival with combined nivolumab and ipilimumab in advanced melanoma. *New England Journal of Medicine, 377*, 1345–1356. https://doi.org/10.1056/NEJMoa1709684

Zhang, P., Ma, Y., Lv, C., Huang, M., Li, M., Dong, B.,...Yang, Y. (2016). Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy. *Cancer Science, 107*(11), 1563–1571. https://doi.org/10.1111/cas.13072

Zhou, Y., Chen, C., Zhang, X., Fu, S., Xue, C., Ma, Y.,...Zhang, L. (2018). Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: A systematic review and meta-analysis. *Journal for ImmunoTherapy of Cancer, 6*(1), 155. https://doi.org/10.1186/s40425-018-0477-9